Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC By Ogkologos - September 3, 2026 3 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 5-year follow-up analysis of the KEYNOTE-564 study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian ESMO Welcomes European Parliament (EP) report on Psychosocial Risks (PSR) at Work as a Key Step towards Protecting the Cancer Workforce and Ensuring High-Quality... FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumours MOST POPULAR Black Women Have Nearly Three Times the Risk of Developing Triple... September 22, 2021 Five Fraction SBRT Noninferior to Moderately Fractionated Image-Guided Radiotherapy for Patients... November 7, 2024 First-Line Treatment with Atezolizumab Associated with Improved OS in Patients with... July 21, 2023 New Treatment Approach Could Help Prevent Recurrences of Some Bladder Cancers May 31, 2018 Load more HOT NEWS MGUS to Myeloma: Study Suggests Risk of Progression Can Change Camrelizumab Plus Rivoceranib Improves Survival Compared with Sorafenib in First-Line Treatment... What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials Significant Benefits of Nivolumab Plus Cabozantinib Over Sunitinib in Previously Untreated...
